• The first natural product described as

  2024-05-07

  

  The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic cabotegravir from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time before mPGES-

• Our data indicate that the

  2024-05-06

  

  Our data indicate that the D1 domain only needs to hydrolyze ATP a few times, or perhaps even just once, during the processing of a given substrate molecule, whereas the D2 domain hydrolyzes ATP many times. Consistent with this model, only D2 contains the canonical aromatic pore loop residues implic

• Human hepatocyte transplantation resulted in some animals wi

  2024-05-06

  

  Human hepatocyte transplantation resulted in some animals with relatively sparse repopulation while others had >90% of their liver containing human hepatocytes. The presence of circulating human albumin varied based on the amount of repopulation as the degree of humanization is reported to correlate

• In our approach using BRET and FRET there is

  2024-05-06

  

  In our approach using BRET and FRET, there is a substantial increase in BRET and FRET signals between Giα2 or Giα3-YFP and CFP- Gγ2/Rluc-Gγ2 upon apelin-13 activation, indicating that Gαi2, Gαi3 and N-terminus of Gβ1γ2 subunits become closer without subunit dissociation. In contrast, both the FRET a

• Our observation that squalestatin caused only

  2024-05-06

  

  Our observation that squalestatin caused only small differences in the production of Aβ40 and Aβ42 was in contrast to prior reports of the effects of other cholesterol synthesis inhibitors. This may be due to using squalestatin, a more specific cholesterol synthesis inhibitor that does not affect is

• br Experimental Procedures br Acknowledgments br Introductio

  2024-05-06

  

  Experimental Procedures Acknowledgments Introduction Cellular and molecular mechanisms underlying synaptic plasticity in the acetylcholine inhibitor are thought to be involved in memory acquisition. Synaptic plasticity is categorised into two main types, long-term depression (LTD) and long

• Here we provide evidence that

  2024-05-06

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• In hypothalamus as indicated in Fig column A and following

  2024-05-06

  

  In hypothalamus, as indicated in Fig. 2 (column A) and following the enzymatic cascade represented in Fig. 1, we could hypothesize a predominance of Ang 2–10 and Ang III formation in SHR compared to WKY. This is in agreement with previous results that reported significant higher rate of Ang 2–10 for

• Epidermal growth factor EGF has been shown to increase the

  2024-05-06

  

  Epidermal growth factor (EGF) has been shown to increase the 12S-lipoxygenase mRNA level by about two-fold in human epidermoid carcinoma A431 cells [71]. This enzyme was shown to be of the platelet-type and associated with the microsomal fraction of the cells [71], [72]. A requirement for EGF recept

• br Discussion The present understanding is that

  2024-05-06

  

  Discussion The present understanding is that patients suffering from AD are at a higher risk for epilepsy than individuals without AD [[1], [2]]. The clinical diagnostic accuracy of AD has improved significantly during the last decades. However, most of the epidemiological studies on these two of

• br Special report Financial and personal benefits of

  2024-05-06

  

  Special report – Financial and personal benefits of early diagnosis Acknowledgments The Alzheimer’s Association acknowledges the contributions of Joseph Gaugler, Ph.D., Bryan James, Ph.D., Tricia Johnson, Ph.D., Allison Marin, Ph.D., and Jennifer Weuve, M.P.H., Sc.D., in the preparation of 201

• Lorlatinib is an orally active

  2024-05-06

  

  Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F

• Many of the cellular processes

  2024-05-06

  

  Many of the cellular processes regulated by AKT activation are also controlled by other intracellular pathways such as the MAPK pathway, the PLCγ pathway, but also, directly or indirectly, by signaling pathways not linked to RTK transmembrane receptors, such as growth factor-linked signaling affecti

• Ketogenic diets are more effective in

  2024-05-06

  

  Ketogenic diets are more effective in promoting weight loss than conventional caloric restriction [26] however, their effect on hepatic glucose and lipid metabolism remains inconclusive. Blood glucose homeostasis is tightly regulated. In both mice and humans consuming KD, baseline blood glucose decr

• The direction of research then turned

  2024-05-06

  

  The direction of research then turned to investigating the long-term effects of adiponectin on insulin resistance. Adiponectin transgenic mice showed a reduction in insulin resistance and diabetes [5,6], while adiponectin-deficient mice showed mild insulin resistance with glucose intolerance, as wel

14060 records 153/938 page Previous Next First page 上5页 151152153154155 下5页 Last page